The big drug complex including Pfizer (PFE), Eli Lilly (LLY), and Wyeth (WYE) are all under fire from generics and they all reporting earnings Thursday. How should you trade?
Guy Adami says he’s bullish on PFE on a valuation basis. “It’s just cheap,” he says, "and I like their dividend."
Pete Najarian believes Biogen (BIIB), Genzyme (GENZ) Isis Pharmaceuticals (ISIS) and Gilead (GILD) are all buys as possible takeover targets.
Got something to say? Send us an e-mail at firstname.lastname@example.org and your comment might be posted on the Rapid Recap! Prefer to keep it between us? You can still send questions and comments to .
Trader disclosure: On Oct 17, 2007, the following stocks and commodities mentioned or intended to be mentioned on CNBC’s Fast Money were owned by the Fast Money traders; Macke Owns (DIS), (INTC), (SWY); Najarian Owns (C), (GOOG); Najarian Owns (CY) Options, (ETFC) Options, (EBAY) Options, (FXI) Options; Finerman Owns (C), (GS); Finerman's Firm Owns (BIIB), (WMT), (TGT), (MO), (CTX), (COP), (LTD), (MSFT); Finerman's Firm And Finerman Own (HD), (ASD); Finerman's Firm Owns S&P 500 Index Puts; Finerman's Firm Owns Russell 2000 Puts